Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2002

View Archived Issues

Transgene's Ad-IFNgamma product candidate enters phase I trial for cutaneous lymphoma

FDA approves Pravachol 80 mg

Onyvax initiates phase II trial of Onyvax P in prostate cancer

First patients treated in phase II trial of PhotoPoint drug MV-9411 in psoriasis

Recurrence data from phase III trial of Polyphenon E show efficacy in genital warts

AIDS drug MDI-P shows no toxicity in preclinical tests

Neoprobe closes acquisition of Biosonix

CT-025 as an effective means of delivering calcitonin by oral administration

Japanese labs discontinue compound for perioperative hypertension

Siderophore-acylaminopenicillins highly active against resistant Gram-negative pathogens

Promising fluoroquinolones emerge from R&D at Indian pharmaceutical company

Preclinical data support further development of P-113D as CF therapy

deCODE Genetics to acquire MediChem Life Sciences

Solaraze now being marketed for actinic keratosis in U.S.

Medarex's tumor vaccine program to evaluate melanoma vaccines in conjunction with MDX-010

Sanofi-Synthelabo transfers Gabitril rights to Cephalon

First human trial yields positive data on L-dT, a potential new therapy for HBV

Epimmune and Rhein Biotech enter research agreement for vaccine development

Pilot study shows Symlin improves daily glucose profile in type 1 diabetes patients

Biovail files NDA for FlashDose version of zolpidem tartrate

Genta files IND for gallium nitrate in NHL

Abbott will manufacture oritavancin under new agreement

Ortho-McNeil claims series of PDE5 inhibitors and use in sexual dysfunction

Inhibitors of MMP enzymes described by Darwin Discovery

Pyrazole-based inhibitors of TNF-alpha signaling particularly useful in multiple sclerosis

Novel series of agents for influenza identified by Sankyo

Selective inhibitors of HSL described by Novo Nordisk team

Recent patents cover new beta3-adrenoceptor agonists designed at Asahi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...